## Jeffery C Talbert

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4456696/publications.pdf

Version: 2024-02-01

		236925	3	302126
98	1,873	25		39
papers	citations	h-index		g-index
100	100	100		2377
100	100	100		23//
all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	Broadband internet subscription rates and opioid prescribing via telemedicine during the COVIDâ€19 pandemic. Journal of Rural Health, 2022, 38, 900-907.	2.9	3
2	Enhancing research data infrastructure to address the opioid epidemic: the Opioid Overdose Network (O2-Net). JAMIA Open, 2022, 5, .	2.0	1
3	Design, Implementation, and Evolution of the Medicaid Outcomes Distributed Research Network (MODRN). Medical Care, 2022, 60, 680-690.	2.4	8
4	Integrating data science into the translational science research spectrum: A substance use disorder case study. Journal of Clinical and Translational Science, 2021, 5, e29.	0.6	5
5	The impact of medical and recreational marijuana laws on opioid prescribing in employerâ€sponsored health insurance. Health Economics (United Kingdom), 2021, 30, 989-1000.	1.7	15
6	Variations in Schedule III prescription patterns in a Medicaid population pre- and post-policy. Scientific Reports, 2021, 11, 7142.	3.3	0
7	"Doctor and pharmacy shopping― A fading signal for prescription opioid use monitoring?. Drug and Alcohol Dependence, 2021, 221, 108618.	3.2	10
8	Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018. JAMA - Journal of the American Medical Association, 2021, 326, 154.	7.4	59
9	Letter to the Editor regarding: Medicaid prescription limits and their implications for naloxone accessibility (by Roberts et al., 2021). Drug and Alcohol Dependence, 2021, 226, 108888.	3.2	1
10	Chronic opioid use is associated with early biologic discontinuation in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2021, 53, 704-711.	3.7	7
11	Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States. Pain Physician, 2021, 24, E249-E256.	0.4	1
12	Identifying Opioid Use Disorder from Longitudinal Healthcare Data using a Multi-stream Transformer AMIA Annual Symposium proceedings, 2021, 2021, 476-485.	0.2	0
13	Predicting substance use disorder using long-term attention deficit hyperactivity disorder medication records in Truven. Health Informatics Journal, 2020, 26, 787-802.	2.1	8
14	Perception of prescription drug monitoring programs as a prevention tool in primary medical care. Research in Social and Administrative Pharmacy, 2020, 16, 1306-1308.	3.0	6
15	Neonatal Abstinence Syndrome and Childhood Mental Health Conditions, 2009–2015: Commercial Versus Medicaid Populations. Psychiatric Services, 2020, 71, 184-187.	2.0	1
16	Operationalizing and selecting outcome measures for the HEALing Communities Study. Drug and Alcohol Dependence, 2020, 217, 108328.	3.2	14
17	The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. Drug and Alcohol Dependence, 2020, 217, 108335.	3.2	50
18	Association between state Medicaid expansion status and naloxone prescription dispensing. Health Services Research, 2020, 55, 239-248.	2.0	12

#	Article	IF	CITATIONS
19	Appalachian disparities in tobacco cessation treatment utilization in Medicaid. Substance Abuse Treatment, Prevention, and Policy, 2020, 15, 5.	2.2	3
20	Using medical claims database to develop a population disease progression model for leuprorelin-treated subjects with hormone-sensitive prostate cancer. PLoS ONE, 2020, 15, e0230571.	2.5	1
21	Title is missing!. , 2020, 15, e0230571.		0
22	Title is missing!. , 2020, 15, e0230571.		0
23	Title is missing!. , 2020, 15, e0230571.		0
24	Title is missing!. , 2020, 15, e0230571.		0
25	Co-prescription network reveals social dynamics of opioid doctor shopping. PLoS ONE, 2019, 14, e0223849.	2.5	12
26	Association of Naloxone Coprescription Laws With Naloxone Prescription Dispensing in the United States. JAMA Network Open, 2019, 2, e196215.	5.9	73
27	Network Abstractions of Prescription Patterns in a Medicaid Population. AMIA Summits on Translational Science Proceedings, 2019, 2019, 524-532.	0.4	2
28	Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings. Drug and Alcohol Dependence, 2018, 184, 26-32.	3.2	50
29	Rural and Appalachian Disparities in Neonatal Abstinence Syndrome Incidence and Access to Opioid Abuse Treatment. Journal of Rural Health, 2018, 34, 6-13.	2.9	76
30	The changing landscape of naloxone availability in the United States, 2011 – 2017. Drug and Alcohol Dependence, 2018, 191, 361-364.	3.2	72
31	Predicting Substance Use Disorder in ADHD Patients using Long-Short Term Memory Model. , 2018, 2018, 49-50.		3
32	Non-retrieval ofÂinferior vena cava filters as a patient safety concern: evaluation of a new process improvement project to increase retrieval rates in a vascular and interventional radiology clinic. Patient Safety in Surgery, 2018, 12, 5.	2.3	0
33	Utilization of free medication samples in the United States in a nationally representative sample: 2009–2013. Research in Social and Administrative Pharmacy, 2017, 13, 193-200.	3.0	13
34	Association of time to antibiotics and clinical outcomes in adult hematologic malignancy patients with febrile neutropenia. Journal of Oncology Pharmacy Practice, 2017, 23, 278-283.	0.9	12
35	Treatment of Opioid Use Disorder During Pregnancy May Increase Cases of Neonatal Abstinence Syndrome—Reply. JAMA Pediatrics, 2017, 171, 707.	6.2	0
36	Using closure tables to enable cross-querying of ontologies in database-driven applications. , 2017, 2017, 493-496.		0

#	Article	IF	Citations
37	Vena Cava Filter Retrieval Rates and Factors Associated With Retrieval in a Large US Cohort. Journal of the American Heart Association, 2017, 6, .	3.7	53
38	Predictors of Chronic Opioid Use in Newly Diagnosed Crohn $\hat{E}^{1}\!\!/\!\!4$ s Disease. Inflammatory Bowel Diseases, 2017, 23, 1004-1010.	1.9	23
39	Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study. Thrombosis Research, 2017, 158, 49-58.	1.7	17
40	Hospital Variation and Patient Characteristics Associated With Vena Cava Filter Utilization. Medical Care, 2017, 55, 31-36.	2.4	7
41	Medicaid program choice, inertia and adverse selection. Journal of Health Economics, 2017, 56, 292-316.	2.7	11
42	Medicaid Managed Care and the Health Care Utilization of Foster Children. Inquiry (United States), 2017, 54, 004695801769855.	0.9	2
43	Empirical Assessment of the Impact of Low-Cost Generic Programs on Adherence-Based Quality Measures. Pharmacy (Basel, Switzerland), 2017, 5, 15.	1.6	0
44	Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 958-967.	0.9	45
45	Immune Checkpoint Inhibition and the Prevalence of Autoimmune Disorders Among Patients With Lung and Renal Cancer. Cancer Informatics, 2017, 16, 117693511771252.	1.9	13
46	Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillinâ€√azobactam: A Retrospective Cohort Analysis. Journal of Hospital Medicine, 2017, 12, 77-82.	1.4	57
47	Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates. JCO Clinical Cancer Informatics, 2017, 1, 1-12.	2.1	9
48	The Prevalence and Predictors of Low-Cost Generic Program Use in a Nationally Representative Uninsured Population. Pharmacy (Basel, Switzerland), 2016, 4, 14.	1.6	1
49	Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data. Journal of Managed Care & Decialty Pharmacy, 2016, 22, 741-751.	0.9	17
50	Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-NaÃ-ve Nonvalvular Atrial Fibrillation. Journal of Managed Care & Decialty Pharmacy, 2016, 22, 1319-1329.	0.9	59
51	National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine (United States), 2016, 95, e3784.	1.0	77
52	A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC Eras. Drugs and Aging, 2016, 33, 427-436.	2.7	28
53	A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy. ADHD Attention Deficit and Hyperactivity Disorders, 2016, 8, 149-158.	1.7	5
54	Rates of Neonatal Abstinence Syndrome Amid Efforts to Combat the Opioid Abuse Epidemic. JAMA Pediatrics, 2016, 170, 1110.	6.2	30

#	Article	IF	CITATIONS
55	Variation in the Use of Vena Cava Filters for Venous Thromboembolism in Hospitals in Kentucky. JAMA Surgery, 2016, 151, 984.	4.3	5
56	Does Medicaid Managed Care Help Equalize Racial and Ethnic Disparities in Utilization?. Health Services Research, 2016, 51, 872-891.	2.0	13
57	Anticoagulation Treatment for Stroke Prevention in Atrial Fibrillation Is Increasing, But Further Improvements Needed. Journal of the American College of Cardiology, 2016, 68, 2492.	2.8	2
58	Using i2b2 to bootstrap rural health analytics and learning networks. , 2016, 2016, 2533-2536.		1
59	A Description and Comparison of Treatments for Low Back Pain in the United States. Orthopaedic Nursing, 2016, 35, 214-221.	0.4	21
60	Informatics-based challenges of building collaborative healthcare research and analysis networks from rural community health centers., 2016, 2016, 513-516.		4
61	Atypical antipsychotic initiation and the risk of type II diabetes in children and adolescents. Pharmacoepidemiology and Drug Safety, 2015, 24, 583-591.	1.9	25
62	Health Considerations in Regulation and Taxation of Electronic Cigarettes. Journal of the American Board of Family Medicine, 2015, 28, 802-806.	1.5	10
63	Online Medical Care: The Current State of "eVisits―in Acute Primary Care Delivery. Telemedicine Journal and E-Health, 2015, 21, 90-96.	2.8	65
64	Mental disorder comorbidity and in-hospital mortality among patients with acute myocardial infarction. Geriatric Mental Health Care, 2015, 3, 7-11.	0.3	5
65	Prescription drug monitoring program utilization in Kentucky community pharmacies. Pharmacy Practice, 2015, 13, 540.	1.5	17
66	Research Partnerships with Healthcare Providers in Rural Community Health Centers Needs and Challenges in Diabetes Research. Public Health Frontier, 2015, 4, 1-6.	0.1	4
67	Law Enforcement Perceptions of a Prescription Drug Monitoring Programme. International Journal of Police Science and Management, 2014, 16, 288-296.	1.3	2
68	Predictors of Consumer Satisfaction in Community Mental Health Center Services. Community Mental Health Journal, 2014, 50, 922-925.	2.0	8
69	A tale of two cities? The heterogeneous impact of medicaid managed care. Journal of Health Economics, 2014, 36, 47-68.	2.7	35
70	Drug Overdose Surveillance Using Hospital Discharge Data. Public Health Reports, 2014, 129, 437-445.	2.5	25
71	Kentucky pharmacists' opinions of the potential reclassification of pseudoephedrine as a legend drug. Journal of the American Pharmacists Association: JAPhA, 2014, 54, 397-405.	1.5	2
72	Healthcare Costs Associated With Chronic Opioid Use and Fibromayalgia Syndrome. American Journal of Pharmacy Benefits, 2014, 6, e177-e184.	1.3	2

#	Article	IF	CITATIONS
73	Geographic Variation of Chronic Opioid Use in Fibromyalgia. Clinical Therapeutics, 2013, 35, 303-311.	2.5	31
74	Screening and Management of Obesity and Perception of Weight Status in Medicaid Recipients. Journal of Health Care for the Poor and Underserved, 2013, 24, 34-46.	0.8	6
75	Pseudoephedrine Sales and Seizures of Clandestine Methamphetamine Laboratories in Kentucky. JAMA - Journal of the American Medical Association, 2012, 308, 1524.	7.4	3
76	The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiology, 2012, 36, e243-e250.	1.9	35
77	The Effects of Medicaid Policy Changes on Adults' Service Use Patterns in Kentucky and Idaho. Medicare & Medicaid Research Review, 2012, 2, E1-E22.	1.3	5
78	Crossing the Chasm: Information Technology to Biomedical Informatics. Journal of Investigative Medicine, 2011, 59, 768-779.	1.6	4
79	The Effects of Medicaid and CHIP Policy Changes on Receipt of Preventive Care among Children. Health Services Research, 2011, 46, 298-318.	2.0	28
80	Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors. Journal of Oncology Pharmacy Practice, 2011, 17, 312-319.	0.9	30
81	Physician Characteristics Associated with Early Adoption of Electronic Medical Records in Smaller Group Practices., 2011,, 182-191.		1
82	CHIP Premiums, Health Status, and the Insurance Coverage of Children. Inquiry (United States), 2010, 47, 199-214.	0.9	9
83	Physician Characteristics Associated with Early Adoption of Electronic Medical Records in Smaller Group Practices., 2010,, 423-432.		0
84	Policy-Related Degree Options for Pharmacists Interested in Careers in the Health Care Field. Hospital Pharmacy, 2010, 45, 135-141.	1.0	1
85	Physician Characteristics Associated with Early Adoption of Electronic Medical Records in Smaller Group Practices. International Journal of Healthcare Information Systems and Informatics, 2009, 4, 69-80.	0.9	3
86	Community Readiness for Local Smoke-Free Policy Change. American Journal of Health Promotion, 2008, 23, 112-120.	1.7	31
87	Trends in Controlled-Release Oxycodone (OxyContinR) Prescribing Among Medicaid Recipients in Kentucky, 1998-2002. Journal of Rural Health, 2006, 22, 276-278.	2.9	23
88	Setting the Legislative Agenda: The Dimensional Structure of Bill Cosponsoring and Floor Voting. Journal of Politics, 2002, 64, 864-891.	2,2	75
89	Look for the Party Label: Party Influences on Voting in the U. S. House. Legislative Studies Quarterly, 2000, 25, 75.	1.2	63
90	The Dimensional Structure of Policy Outputs: Distributive Policy and Roll Call Voting. Political Research Quarterly, 2000, 53, 695.	1.7	0

#	Article	IF	CITATIONS
91	The Dimensional Structure of Policy Outputs: Distributive Policy and Roll Call Voting. Political Research Quarterly, 2000, 53, 695-710.	1.7	19
92	Witnesses at the Confirmations? The Appearance of Organized Interests at Senate Hearings of Federal Judicial Appointments, 1945-1992. Political Research Quarterly, 1998, 51, 617-631.	1.7	7
93	Congressional Caucuses in National Policy Makingby Susan Webb Hammond. Political Science Quarterly, 1998, 113, 326-327.	0.2	O
94	Partisan Differences in Candidate Quality in Open Seat House Races, 1976-1994. Political Research Quarterly, 1997, 50, 281-299.	1.7	50
95	Congressional Partisanship and the Failure of Moderate Health Care Reform. Journal of Health Politics, Policy and Law, 1995, 20, 1033-1050.	1.9	0
96	Nonlegislative Hearings and Policy Change in Congress. American Journal of Political Science, 1995, 39, 383.	4.5	101
97	From Setting a National Agenda on Health Care to Making Decisions in Congress. Journal of Health Politics, Policy and Law, 1995, 20, 437-445.	1.9	8
98	The Destruction of Issue Monopolies in Congress. American Political Science Review, 1993, 87, 657-671.	3.7	122